True North Labs

Author: labstruenorth@gmail.com

  • New Clinical Trial Explores Combination Approach for Treatment-Resistant Prostate Cancer

    A newly launched clinical trial, known as the COSMYC Trial, is investigating a promising combination strategy for patients facing castration-resistant prostate cancer — a challenging form of the disease that no longer responds to standard hormone-suppressing treatments. The study aims to determine whether sequencing therapies in a novel order can improve outcomes for patients who have run out of many conventional options.

    The trial design is notable for its innovative approach: researchers will first administer a combination of testosterone and the investigational compound ZEN-3694, followed by a second phase combining enzalutamide with ZEN-3694. The hypothesis is that this specific sequencing may prime tumors to respond more effectively to the subsequent enzalutamide-based treatment, potentially enhancing the overall anti-cancer effect compared to standard approaches.

    ZEN-3694 belongs to a class of drugs known as BET inhibitors, which work by targeting proteins involved in the regulation of cancer-related genes, including MYC — a gene frequently implicated in aggressive and treatment-resistant cancers. By pairing this mechanism with hormone therapy in a carefully planned sequence, researchers hope to outsmart the biological pathways that allow prostate cancer cells to resist standard treatments.

    This kind of research reflects a broader and encouraging trend in oncology: the exploration of smart combination and sequencing strategies rather than relying on a single drug alone. For patients with castration-resistant disease, who often face limited treatment options, trials like COSMYC represent meaningful efforts to expand what’s possible and potentially extend the effectiveness of existing therapies through thoughtful scientific design.

    While it will take time before results are available, the launch of this trial is a hopeful sign of continued innovation in prostate cancer research. Patients and clinicians interested in learning more can find additional details through the official clinical trial registry. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: The COSMYC Trial (COmbined Suppression of MYC)

  • HHS Signals Broader Access to Popular Wellness Peptides

    In a development that peptide enthusiasts have been watching closely, the U.S. Department of Health and Human Services (HHS) has announced that some wellness peptides are set to become more widely available. While details are still emerging, the announcement signals a potential shift toward easier access for a category of products that many people use as part of their personal wellness routines.

    Peptides have grown in popularity over the past several years, with interest spanning everything from recovery and performance to general wellness support. However, access has often been inconsistent, with some products available only through specialized channels or compounding pharmacies. A move by HHS toward broader availability could mean more consistent access for people who have been seeking these products through legitimate avenues.

    For the peptide community, regulatory clarity is often just as valuable as access itself. When agencies like HHS weigh in on how certain products should be classified or distributed, it can pave the way for more standardized quality control, clearer labeling, and a more predictable marketplace overall. That kind of structure tends to benefit consumers by making it easier to find trustworthy sources and understand what they’re purchasing.

    This announcement also reflects a broader trend of regulatory bodies paying closer attention to the wellness peptide space, which has historically existed somewhat on the margins of conventional healthcare regulation. Increased attention from HHS could be a sign that peptides are being taken more seriously as a legitimate category within the broader wellness and health products industry, potentially opening doors for further research, product development, and innovation down the line.

    As more information becomes available about which specific peptides will see expanded availability and under what conditions, True North Labs will continue to monitor the situation and provide updates. In the meantime, this development is an encouraging sign for those who value both access and oversight when it comes to wellness products. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Some wellness peptides will become widely available, HHS says – ABC News – Breaking News, Latest News and Videos

  • HHS Draft Policy Signals Easier Access to Six Compounded Peptides

    The U.S. Department of Health and Human Services (HHS) has released a draft policy that would ease enforcement restrictions on six compounded peptides, a move that could expand access to these therapies through licensed compounding pharmacies. The news comes as welcome relief to patients, practitioners, and researchers who have watched peptide availability tighten in recent years amid regulatory uncertainty.

    Compounded peptides have become an important option for patients who need personalized dosing or formulations that are not available through traditional commercial drug channels. By easing enforcement on this specific set of six peptides, HHS appears to be acknowledging the legitimate role that compounding pharmacies play in bridging gaps in the broader pharmaceutical supply chain, particularly for specialty treatments where standardized commercial products may not fully meet patient needs.

    While the draft policy does not amount to full regulatory approval of these peptides as FDA-sanctioned drugs, easing enforcement can meaningfully reduce friction for compounding pharmacies that have been navigating a complex and sometimes inconsistent regulatory landscape. For practitioners who prescribe peptide-based protocols, this could mean more reliable sourcing and fewer disruptions in patient care, assuming compounders continue to meet quality and safety standards required under compounding law.

    This development is also a positive signal for the broader peptide field, suggesting that regulators are willing to engage thoughtfully with the nuances of peptide therapeutics rather than applying blanket restrictions. As the draft policy moves through further review, stakeholders including pharmacists, physicians, and patient advocacy groups will likely be watching closely to see which six peptides are named and how the final guidance is implemented.

    For now, this draft policy represents an encouraging step toward more predictable and patient-friendly access to compounded peptide therapies. As always, any decisions about peptide use should be made in consultation with a qualified healthcare provider, and this article is for informational purposes only and not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: HHS Draft Policy Eases Enforcement on 6 Compounded Peptides – The American Journal of Managed Care

  • HHS Signals Expanded Access to Compounded Peptides

    The U.S. Department of Health and Human Services has taken steps toward allowing the compounding of select peptides that have not yet received full FDA approval, according to a recent report from STAT News. This move could mark a meaningful shift in how patients and providers access certain peptide-based therapies that have shown promise but remain outside traditional approval pathways.

    Compounding pharmacies play a crucial role in the U.S. healthcare system, allowing licensed pharmacists to create customized medications tailored to individual patient needs. By opening the door to compounding certain peptides, HHS appears to be recognizing the growing interest in these molecules and their potential therapeutic applications, while still working within a regulatory framework designed to ensure safety and quality standards.

    This development is particularly encouraging for the peptide research and medical communities, as it may help bridge the gap between promising scientific research and patient access. Peptides have been studied for a wide range of potential applications, and easier pathways for compounding could allow more patients to work with their healthcare providers to explore these options under appropriate medical supervision.

    For patients and practitioners who have followed the evolving regulatory landscape around peptides, this signals a potentially more accommodating stance from federal health authorities. It suggests an ongoing dialogue about how to balance innovation and access with necessary safety oversight—a balance that, when achieved well, benefits both the scientific community and patients seeking new treatment options.

    As this policy continues to develop, we’ll be watching closely for further details on which specific peptides may be included and what safeguards will accompany expanded compounding access. This is an encouraging sign for the future of peptide-based care in the United States.

    This article is for informational purposes only and is not medical advice. Please consult a qualified healthcare provider for guidance specific to your situation.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: HHS moves to allow compounding of some unapproved peptides – STAT

  • HHS Expands Access to Select Unapproved Peptides, Opening New Doors for Patients and Practitioners

    In a notable regulatory shift, U.S. Health Secretary Robert F. Kennedy Jr. has taken steps to open access to a select group of unapproved peptides, according to a new Reuters report. The move signals a potential easing of restrictions that have long limited availability of certain peptide compounds, which have grown in popularity for their roles in areas ranging from recovery and metabolic support to general wellness.

    Peptides have increasingly captured attention from both researchers and the public due to their highly targeted biological activity and relatively favorable safety profiles compared to many broader pharmaceutical interventions. However, many promising peptides have remained in a regulatory gray area, available only through specialized compounding pharmacies or research channels, limiting broader patient access. This policy shift suggests regulators may be recognizing growing patient and provider interest in these therapies.

    For the peptide community, including clinicians, compounding pharmacists, and patients who have sought these therapies for specific health goals, expanded access could mean more consistent and legitimate pathways to obtain certain compounds. This could also encourage additional research and clinical interest, as greater access often correlates with more real-world data collection and manufacturer investment in formal studies.

    While specific details about which peptides are affected and the exact scope of the policy change continue to emerge, the broader trend reflects a more flexible regulatory posture toward peptide therapies at the federal level. Advocates within the peptide and integrative medicine communities have long called for clearer, more accessible frameworks that balance patient safety with innovation and access.

    True North Labs will continue to monitor developments on this story as more details become available, including which specific peptides are impacted and how healthcare providers and compounding pharmacies may adapt to the updated guidance. As always, this article is for informational purposes only and is not intended as medical advice. Please consult a qualified healthcare provider before starting or changing any peptide-related therapy.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: US Health Secretary Kennedy opens access to some unapproved peptides – Reuters

  • Expanded Access: Pharmacies Permitted to Compound Popular Peptides

    In a development that could reshape access to peptide-based therapies, the current administration has announced a policy allowing pharmacies to compound certain popular peptides. This means pharmacies with compounding capabilities may now be able to prepare these formulations for patients under appropriate medical guidance, rather than relying solely on commercially manufactured products.

    For many patients and practitioners, compounding pharmacies serve as an important bridge when commercial supply is limited or when individualized dosing is needed. Peptides have grown enormously in popularity in recent years thanks to promising research into their roles in metabolic health, recovery, and other wellness applications. Allowing broader compounding access could help ease bottlenecks that have sometimes left patients waiting or searching for alternatives.

    Compounding pharmacies operate under specific regulatory standards designed to ensure quality and safety, and this policy shift suggests regulators see a path to maintaining oversight while expanding availability. For the peptide community—including researchers, clinicians, and patients—this kind of regulatory clarity can be encouraging, as it may reduce uncertainty around sourcing and support more consistent access to these compounds through licensed pharmacy channels.

    Industry observers note that expanded compounding access often goes hand-in-hand with continued innovation, as it can allow for more tailored approaches to patient care while commercial manufacturers scale up production of popular formulations. This kind of flexibility has historically been valuable in fields ranging from hormone therapy to specialty medications, and peptides may now benefit from a similar framework.

    As this policy rolls out, patients and providers will likely want to stay informed about which specific peptides are covered and what quality standards apply. True North Labs will continue to track developments in this space as more details emerge. This article is for informational purposes only and is not medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Trump administration will allow pharmacies to make popular peptides – NPR

  • Longevity Expert David Sinclair Highlights Promising Peptides Backed by Emerging Science

    The world of longevity science continues to generate excitement, and one of its most recognized voices, Harvard researcher David Sinclair, is now turning attention toward peptides as a potential next frontier. Sinclair, known for his decades of work studying aging and cellular health, has suggested that certain peptides could have an impact on healthy aging similar to the way GLP-1 medications reshaped the conversation around weight management.

    This comparison matters because GLP-1 drugs demonstrated how a single class of compounds could shift both scientific understanding and public interest in metabolic health. Sinclair’s comments point to a similar possibility for peptides that may support cellular repair, tissue health, and other processes tied to aging. While research in this area is still developing, the growing interest from respected scientists reflects a broader momentum building around peptide-based approaches to wellness and longevity.

    According to the report, a handful of specific peptides are already drawing attention for their early scientific backing. These compounds are being studied for their potential roles in areas such as cellular signaling, recovery, and metabolic support. Researchers emphasize that peptides are being explored for their precision—many are designed to interact with very specific biological pathways, which could make them useful tools as scientists continue to unravel the complex mechanisms behind aging.

    What’s particularly encouraging is the increasing collaboration between longevity researchers and the broader scientific community to rigorously evaluate these compounds. As peptide science matures, so does the infrastructure supporting it—from more refined research methodologies to growing interest from investors and institutions eager to support promising avenues in aging research. This kind of attention often accelerates the pace of discovery, bringing more clarity to how these molecules function in the human body.

    For the peptide research community, endorsements and insights from high-profile scientists like Sinclair can serve as a valuable signal, helping direct both funding and research attention toward promising compounds. While much work remains to fully understand the long-term effects and applications of these peptides, the growing scientific curiosity represents a hopeful sign for the future of longevity research. As always, developments like these underscore the importance of continued rigorous study, and anyone interested in these topics should look forward to more detailed findings as research progresses.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: David Sinclair Predicts Peptides Could Do for Longevity What GLP-1 Did for Weight Loss. Here Are 3 With Real Science Behind Them – BoxLife Magazine

  • Gilead’s $1.3B Bet on an Oral Peptide Signals Growing Confidence in Immunology Treatments

    In a move that underscores the growing confidence major pharmaceutical companies have in peptide-based therapeutics, Gilead Sciences has announced a $1.3 billion deal to acquire rights to an oral peptide drug candidate designed to treat immunology-related conditions. The investment positions the compound as a potential competitor to an existing immunology pill from Johnson & Johnson, signaling that peptide science continues to attract serious capital and attention from industry leaders.

    Oral peptide formulations represent an exciting frontier in drug development. Historically, peptides have required injection because they can break down in the digestive system before reaching their target. Advances in formulation technology have made it increasingly possible to deliver peptide therapies in pill form, which could make treatments more convenient and accessible for patients who might otherwise need regular injections.

    Gilead’s willingness to commit over a billion dollars to this compound reflects broader optimism in the biotech and pharmaceutical sectors about the therapeutic potential of peptides for complex conditions like immune and inflammatory disorders. Major acquisitions of this scale typically follow careful due diligence, suggesting that the underlying science and early data supporting this peptide candidate have impressed industry experts enough to justify significant financial backing.

    This kind of investment also tends to accelerate research and development timelines. With substantial resources behind it, the oral peptide candidate may move through further clinical evaluation more efficiently, potentially bringing new treatment options to patients sooner. Competition in the immunology space, especially between innovative peptide-based approaches and existing treatments, can also drive continued innovation and improvements in patient care options.

    For the broader peptide therapeutics field, deals like this one serve as an encouraging signal. They demonstrate that pharmaceutical companies see long-term value and viability in peptide-based drug development, which could pave the way for increased research funding and more oral peptide options across various therapeutic areas in the future.

    This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Gilead to Pay $1.3B for Oral Peptide That Could Rival J&J’s New Immunology Pill – MedCity News

  • Gilead Invests $1.3B in Promising Oral Peptide Therapy Targeting IL-23

    In a significant vote of confidence for peptide-based medicine, biopharmaceutical giant Gilead Sciences has announced a licensing deal worth $1.3 billion upfront to secure rights to an experimental oral peptide developed by PepStar. The peptide targets interleukin-23 (IL-23), a protein involved in several inflammatory and autoimmune conditions, and is designed to compete with existing injectable biologics in this therapeutic space.

    What makes this development particularly exciting for the peptide field is the oral delivery format. IL-23 inhibitors have traditionally been delivered via injection, requiring patients to administer or receive shots on a regular schedule. An effective oral peptide alternative could offer a more convenient treatment option for patients managing chronic inflammatory conditions, potentially improving treatment adherence and quality of life.

    This deal also reflects the broader momentum building behind oral peptide technology as a scientific discipline. Historically, peptides have faced challenges with oral bioavailability due to degradation in the digestive system, which is why injectable formulations have dominated this class of therapeutics. Major pharmaceutical investments like this one suggest that advances in peptide engineering and formulation science are successfully overcoming these longstanding hurdles.

    Gilead’s substantial upfront commitment signals strong institutional confidence in both the specific molecule and the underlying oral peptide platform technology. Such investments often accelerate further research and development, potentially paving the way for additional oral peptide candidates targeting other therapeutic areas in the future. As the peptide therapeutics landscape continues to evolve, partnerships of this scale help validate the scientific and commercial viability of this approach.

    This article is for informational purposes only and does not constitute medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Gilead to pay $1.3B upfront for PepStar’s oral IL-23 challenger to J&J’s Icotyde – Fierce Biotech

  • New Pediatric Trial Launches to Test Sonrotoclax for Relapsed Childhood Leukemia

    A new clinical trial has opened to study sonrotoclax (BGB-11417) in children and adolescents facing relapsed or refractory acute myeloid leukemia (AML) and B-cell acute lymphoblastic leukemia (ALL). These are forms of blood cancer that can be especially challenging to treat once they return after initial therapy or fail to respond, making new investigational approaches like this one meaningful for families and care teams searching for additional options.

    The trial will evaluate sonrotoclax in combination with other established anti-cancer medicines, with researchers closely tracking safety, tolerability, and how the body absorbs, processes, and clears the drug. Participants will undergo regular monitoring, including physical exams, blood tests, and heart health checks, ensuring that safety remains a central focus throughout the study. Researchers will also assess how well the combination therapy helps reduce or eliminate leukemia in these young patients.

    What makes this study particularly encouraging is its focus on a patient population that often has limited treatment pathways. By specifically designing a trial for children and adolescents—rather than relying solely on data from adult studies—researchers aim to generate dedicated safety and efficacy information for this age group. Participants will continue treatment for as long as it provides benefit and side effects remain manageable, reflecting a patient-centered approach to care.

    Early-phase trials like this one play a critical role in the broader drug development pipeline. They help determine whether a promising compound can be safely combined with existing therapies and whether it shows signals of effectiveness that could support larger studies down the road. For families affected by pediatric leukemia, the launch of this trial represents another step forward in the ongoing effort to expand treatment possibilities for relapsed or hard-to-treat cases.

    As with all clinical research, results will take time to emerge, and enrollment and outcomes will be closely monitored by the research team. This article is for informational purposes only and is not intended as medical advice.

    Curated by True North Labs. More at truenorthlabs.co. Informational only – not medical advice.

    Source: Clinical Trial: A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia